Convelo Therapeutics
Cleveland, US · Delaware corporation · 3 known investors
Convelo Therapeutics develops remyelination-enhancing therapies that target the central nervous system's myelination pathway to repair nerve damage in people with multiple sclerosis. The company operates a drug discovery platform focused on neurological disorders and originated from research at Case Western Reserve University.
Founders & leadership
PT
Paul TesarCo-founder (Professor, PhD)
DA
Drew AdamsCo-founder (Professor, PhD)
DR
Derrick RossiLeader/Executive
TS
Tracy SaxtonChief Operating Officer
EM
Ed MokHead of Finance
SS
Samantha StubblefieldVP of Operations and Business Development
RR
Ronald RichardNamed on SEC filing
BS
Bill SanfordNamed on SEC filing
SL
Steven LandauNamed on SEC filing
Investors · 3
Reported raises · per SEC filings
Form D private placements$12.8M disclosed across 2 rounds · 2017–2022
▶$10.8MraisedDec 2022 · 1 investors · Other Health CareRule 506(b)
▶$10.8MraisedDec 2022 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Drew AdamsDirector
- Ronald RichardDirector
- Paul TesarDirector
- Derrick RossiDirector
- Bill SanfordDirector
- Offering amount
- $12M
- Amount sold
- $10.8M
- Minimum investment
- $50K
- Proceeds to insiders
- $400K
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedDec 2017 · 1 investors · Other Health CareRule 506(b)
▶$2MraisedDec 2017 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Drew AdamsDirector
- Paul TesarDirector
- Ronald RichardDirector
- Bill SanfordDirector
- Derrick RossiExecutive Officer, Director
- Steven LandauExecutive Officer
- Offering amount
- $15M
- Amount sold
- $2M
- First sale
- Nov 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Convelo Therapeutics do?
- Convelo Therapeutics develops remyelination-enhancing therapies that target the central nervous system's myelination pathway to repair nerve damage in people with multiple sclerosis. The company operates a drug discovery platform focused on neurological disorders and originated from research at Case Western Reserve University.
- Who founded Convelo Therapeutics?
- Convelo Therapeutics was founded by Paul Tesar, Drew Adams.
- Who are Convelo Therapeutics's investors?
- Convelo Therapeutics's investors include CWRU Technology Ventures, JobsOhio Ventures, Jumpstart Ventures.
- How much funding has Convelo Therapeutics raised?
- Convelo Therapeutics has disclosed $12.8M raised across 2 rounds.
- Where is Convelo Therapeutics headquartered?
- Convelo Therapeutics is headquartered in Cleveland, US.